Arecor Announces Transfer Of Novel Therapeutic Product To Hikma
FTSE 250 company Hikma have triggered the transfer of Arecors's AT307 product including a milestone payment.
Arecor Proposed Acquisition of Tetris Pharma Ltd
Arecor move to acquire Tetris Pharma Ltd to add key commercial diabetes product and build out Arecor's specialty hospital products franchise.
Arecor announces positive results from Phase 1 Trial of insulin product for diabetes patients
Arecor announces positive headline results from first phase 1 clinical trial of AT278 ultra-rapid acting insulin candidate for diabetes. AT278 delivers significantly accelerated PK/PD profile compared to Novorapid Potential to be first concentrated (500U/mL) ultra-rapid acting insulin product enabling miniaturisation of next generation insulin delivery devices. Potential to enable more effective disease management for insulin … Continued
Arecor Announce US Phase 1 Trial
Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces U.S. Food and Drug Administration (FDA) clearance of the Group’s Investigational New Drug (IND) application for AT247, the Group’s proprietary wholly owned ultra-rapid insulin for the treatment of diabetes. The IND supports a Phase I clinical trial in … Continued
Calculus invests in Arecor following successful IPO
Arecor announced its admission to trading on AIM, a market operated by London Stock Exchange, on 3 June 2021. Admission follows a successful oversubscribed placing by Panmure Gordon, raising gross proceeds of £20 million at a price of 226 pence per share. On Admission the Company will have a market capitalisation of approximately £62.5 million. … Continued